Reuters09-26
Sept 25 (Reuters) - U.S. drugmaker Pfizer said on Wednesday it was voluntarily withdrawing all lots of its therapy Oxbryta, used for the treatment of sickle cell disease, in all markets where it is approved.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Mohammed Safi Shamsi)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial